Tom Gallen
Managing Editor, Europe
Latest From Tom Gallen
Reckitt Sees R&D Investment Translate To Volume Growth
R&D investments behind consumer health brands such as Nurofen and Durex pay off for Reckitt in Q1 as it sees volume growth across majority of portfolio.
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Euro Q1 Consumer Health Earnings Preview: Reckitt, Sanofi, Haleon, Bayer
Major Europe-based consumer health players Reckitt, Sanofi, Haleon and Bayer feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q1 2024 results over the coming weeks.
Marinomed Takes Virus-Blocking Device Into Allergy And Dry Eye Categories
Virus-blocking compound Carragelose, out-licensed to major consumer health players such as Perrigo and Reckitt for use in OTC respiratory nasal sprays, is being adapted for use in the dry eye and allergy categories.
Swisse Supplements Take Bigger Slice Of Chinese Market
Australian-heritage Swisse grew its share of China's supplements market in 2023 by delivering tailored products to an increasingly health conscious population.
UK Proposes Accelerating Authorizations Of Novel Supplements Like CBD
UK Food Standards Agency proposes shaving a minimum of three months off novel food authorization procedure as part of wider plans to shake-up the process for products like CBD supplements.